Shell Game: Difficult Time For Reverse Mergers
This article was originally published in The Pink Sheet Daily
Executive Summary
Reverse mergers are an increasingly common fundraising strategy for biotech. But do they pay off?
You may also be interested in...
Deals Of The Week: Evolva/Arpida; Genzyme/Targeted Genetics; Biotechnol/Digna Biotech/Genentech
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: Evolva/Arpida; Genzyme/Targeted Genetics; Biotechnol/Digna Biotech/Genentech
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
With Reverse Merger Complete, Transcept Looks To Partner Intermezzo
Newly public specialty firm anticipates annual U.S. sales of $600 million for middle-of-night sleep aid.